Suppr超能文献

[2007年法国透析和肾脏移植的费用,腹膜透析和移植增加的影响]

[The cost of dialysis and kidney transplantation in France in 2007, impact of an increase of peritoneal dialysis and transplantation].

作者信息

Blotière Pierre-Olivier, Tuppin Philippe, Weill Alain, Ricordeau Philippe, Allemand Hubert

机构信息

Caisse nationale de l'assurance maladie des travailleurs salariés, direction de la stratégie des études et des statistiques, 26-50, avenue du Professeur André-Lemierre, 75986 Paris cedex 20, France.

出版信息

Nephrol Ther. 2010 Jul;6(4):240-7. doi: 10.1016/j.nephro.2010.04.005. Epub 2010 May 31.

Abstract

INTRODUCTION

This study estimates the costs for the national health insurance in 2007 of the patients with end-stage renal disease (ESRD) according to therapies modalities.

METHOD

Data for all patients covered by the general health insurance scheme (77% of the French population) from hospital discharge and outpatients reimbursement databases were linked. ESRD therapies were identified using an algorithm mainly based on discharge diagnosis and immunosuppressive drugs refunds.

RESULTS

Extrapolated to all French population at the end of 2007, 60,900 patients had an ESRD therapy: 30,900 were treated on haemodialysis (HD) (51%), 2600 on peritonea dialysis (DP) (4%) and 27,300 had a kidney transplant (45%). Patients with dialysis therapies had more often complementary universal coverage for low earners. According to the French regions, patient treated with DP were between 0 to 26% and 19 to 57% for those with a transplant. The total refund cost for National Health Insurance was four billion euro of which 77% for HD. Annual mean costs per patient were 64 keuro for DP, 89 keuro for HD, 86 keuro for the year of transplantation and 20 keuro for the following years. A 25% increase of DP would allow a decrease of the annual cost of 155 millions euro and 900 transplantations more each year during 10 years a decrease of 2.5 billions euro.

CONCLUSION

The increase of ESRD prevalence and its total cost require patients and professionals information and formation about the less expensive and more autonomous therapies and others alternatives facing the lack of kidney transplants from deceased donors.

摘要

引言

本研究根据治疗方式估算了2007年终末期肾病(ESRD)患者的国民健康保险费用。

方法

将一般健康保险计划覆盖的所有患者(占法国人口的77%)的医院出院数据和门诊报销数据库的数据进行关联。使用主要基于出院诊断和免疫抑制药物报销的算法来识别ESRD治疗。

结果

推算至2007年底的所有法国人口,有60,900名患者接受了ESRD治疗:30,900名接受血液透析(HD)治疗(51%),2600名接受腹膜透析(DP)治疗(4%),27,300名接受肾移植(45%)。接受透析治疗的患者更常获得针对低收入者的补充全民保险。根据法国各地区的数据,接受DP治疗的患者比例在0%至26%之间,接受移植的患者比例在19%至57%之间。国民健康保险的总报销费用为40亿欧元,其中HD占77%。DP患者的年均费用为64,000欧元,HD患者为89,000欧元,移植当年患者为86,000欧元,之后年份为20,000欧元。DP治疗增加25%将使每年费用降低1.55亿欧元,并且在10年内每年可多进行900例移植手术,费用降低25亿欧元。

结论

ESRD患病率及其总成本的增加需要让患者和专业人员了解在缺乏已故捐赠者肾脏移植的情况下,费用较低且自主性更强的治疗方法及其他替代方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验